Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 14,953 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Clear all
Recruiting Phase 1Phase 2 Interventional

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

NCT05691491
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Temozolomide, Tuvusertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Irvine, California • La Jolla, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Recruiting No phase listed Observational

Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

NCT04662918
View directory record Official record
Conditions
GastroIntestinal Bleeding
Interventions
Not listed
Lead sponsor
Xingshun Qi
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

NCT01767103
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Ferriprox®
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional Results available

AXIOS Stent & Delivery System Study

NCT01419769
View directory record Official record
Conditions
Pancreatic Pseudocyst(s)
Interventions
AXIOS Stent & Delivery System
Device
Lead sponsor
Xlumena, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

NCT06642610
View directory record Official record
Conditions
Prediabetes, Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
Interventions
CGM Dynamic Index (CDI)
Device
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Completed No phase listed Observational

Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients

NCT02055560
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, 5-FU Containing Therapy Regimens
Interventions
Not listed
Lead sponsor
Saladax Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
La Jolla, California • Skokie, Illinois • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 2 Interventional

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

NCT00091182
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer
Interventions
oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 25, 2026, 10:30 PM EDT
Withdrawn Not applicable Interventional

The Effectiveness of the Jamboxx Respiratory Therapy Device: Study 2

NCT03522480
View directory record Official record
Conditions
Cystic Fibrosis in Children
Interventions
Jamboxx Respiratory Therapy Device, Autogenic Draining Training
Device · Other
Lead sponsor
My Music Machines Inc.
Industry
Eligibility
5 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 25, 2026, 10:30 PM EDT
Active, not recruiting No phase listed Observational

Predicting Effective Therapy in Pancreatic Cancer

NCT03033927
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
CTC isolocation and analysis
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional

The Effect of Time-restricted Eating on Liver Metabolism

NCT04997486
View directory record Official record
Conditions
NAFLD, Obesity, Nutritional and Metabolic Diseases
Interventions
Time restricted eating
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 2 Interventional

Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

NCT00054873
View directory record Official record
Conditions
Esophageal Neoplasms, Stomach Neoplasms, Adenocarcinoma
Interventions
tezacitabine, 5-fluorouracil
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
29
States / cities
Birmingham, Alabama • Tucson, Arizona • Glendale, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2006 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization

NCT00829413
View directory record Official record
Conditions
Liver Neoplasms
Interventions
SonoVue®
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 25, 2026, 10:30 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B

NCT03778879
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Pancreas Cancer
Interventions
CCX872-B
Drug
Lead sponsor
Alan Katz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional

STRONG Program for Cancer Patients

NCT05649969
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Consultations with Moffitt Dietician, Daily Food Intake Diary with Fitbit smartphone application, Questionnaires
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

NCT00253383
View directory record Official record
Conditions
Cancer
Interventions
counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 2 Interventional

Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

NCT00761241
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy, Pancreaticoduodenectomy
Drug · Biological · Radiation + 1 more
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

NCT04704154
View directory record Official record
Conditions
Solid Tumors
Interventions
Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional Results available

Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction

NCT01038713
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Biliary stent placement
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study Evaluating the Impact of a Prebiotic Soda on Gastrointestinal Symptoms in Users of GLP-1 Agonists

NCT07744360
View directory record Official record
Conditions
GI Symptoms
Interventions
Prebiotic Soda
Other
Lead sponsor
Olipop, PBC
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Terminated Phase 2 Interventional

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT00084461
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Regional Gastrointestinal Carcinoid Tumor, Somatostatinoma
Interventions
romidepsin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

SD Cystic Fibrosis Study

NCT00605761
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SB656933
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Palo Alto, California • Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 2 Interventional

Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

NCT00096070
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
radiation therapy, oxaliplatin, fluorouracil, gemcitabine hydrochloride
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

NCT04708470
View directory record Official record
Conditions
Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV, Anal Cancer, Cervical Cancer, Penile Cancer, Vulvar Cancer, Vaginal Cancer, Colon Cancer
Interventions
Bintrafusp Alfa, PDS01ADC, Entinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Not listed Phase 2 Interventional

Secretin for Acute Pancreatitis

NCT03686618
View directory record Official record
Conditions
Pancreatitis, Acute
Interventions
Secretin
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 25, 2026, 10:30 PM EDT